PMID- 19214504
OWN - NLM
STAT- MEDLINE
DCOM- 20090813
LR  - 20240426
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 58
IP  - 10
DP  - 2009 Oct
TI  - The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as 
      prognostic factor in patients with advanced malignant melanoma.
PG  - 1599-608
LID - 10.1007/s00262-009-0669-8 [doi]
AB  - PURPOSE: We have previously demonstrated an association of the human leukocyte 
      antigen (HLA), HLA-A2 allele with ovarian and prostate cancer mortality as well 
      as a segregation of the ancestral HLA haplotype (AHH) 62.1 [(A2) B15 Cw3 DRB1*04] 
      in patients with stage III-IV serous ovarian cancer. The objective of the present 
      study was to determine the role of the HLA phenotype on the prognosis in stage 
      III-IV malignant melanoma patients. PATIENTS AND METHODS: A cohort of metastatic 
      malignant melanoma patients (n = 91), in stage III (n = 26) or IV (n = 65) were 
      analysed for HLA-A, -B, -Cw and -DRB1 types by PCR/sequence-specific primer 
      method. The frequencies of HLA alleles in the patients were compared to that of 
      healthy Swedish bone marrow donors. The effect of HLA types on prognosis was 
      defined by Kaplan-Meier and Cox analysis. RESULTS: The presence of the AHH 62.1 
      in clinical stage IV patients was significantly and independently associated with 
      the worst survival rate recorded from the appearance of metastasis (HR = 2.14; CI 
      = 1.02-4.4; P = 0.04). In contrast, the period from the primary diagnosis to 
      metastasis was the longest in patients with this haplotype (HR = 0.40; CI = 
      0.17-0.90; P = 0.02). CONCLUSIONS: Melanoma patients in our cohort with 62.1 AHH 
      which is associated with autoimmune diseases have an initial strong anti-tumour 
      control with longer metastasis-free period. These patients have rapid progression 
      after the appearance of metastasis, responding poorly to chemo- or/and 
      immunotherapy. This apparently paradoxical clinical process could be due to the 
      interplay between tumour clones escape and immune surveillance ending up with a 
      rapid disease progression.
FAU - Helgadottir, Hildur
AU  - Helgadottir H
AD  - Department of Oncology-Pathology, Karolinska Institute, Radiumhemmet, Karolinska 
      University Hospital, 171 76, Stockholm, Sweden.
FAU - Andersson, Emilia
AU  - Andersson E
FAU - Villabona, Lisa
AU  - Villabona L
FAU - Kanter, Lena
AU  - Kanter L
FAU - van der Zanden, Henk
AU  - van der Zanden H
FAU - Haasnoot, Geert W
AU  - Haasnoot GW
FAU - Seliger, Barbara
AU  - Seliger B
FAU - Bergfeldt, Kjell
AU  - Bergfeldt K
FAU - Hansson, Johan
AU  - Hansson J
FAU - Ragnarsson-Olding, Boel
AU  - Ragnarsson-Olding B
FAU - Kiessling, Rolf
AU  - Kiessling R
FAU - Masucci, Giuseppe Valentino
AU  - Masucci GV
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090213
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HLA-A Antigens)
RN  - 0 (HLA-B Antigens)
RN  - 0 (HLA-C Antigens)
RN  - 0 (HLA-Cw1 antigen)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (HLA-DRB1 Chains)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/genetics
MH  - Cohort Studies
MH  - Female
MH  - HLA-A Antigens/*genetics
MH  - HLA-B Antigens/*genetics
MH  - HLA-C Antigens/*genetics
MH  - HLA-DR Antigens/*genetics
MH  - HLA-DRB1 Chains
MH  - Haplotypes/*genetics
MH  - Humans
MH  - Male
MH  - Melanoma/*genetics/mortality
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Polymerase Chain Reaction
MH  - Prognosis
MH  - Survival Rate
PMC - PMC11030936
EDAT- 2009/02/14 09:00
MHDA- 2009/08/14 09:00
PMCR- 2009/02/13
CRDT- 2009/02/14 09:00
PHST- 2008/12/01 00:00 [received]
PHST- 2009/01/21 00:00 [accepted]
PHST- 2009/02/14 09:00 [entrez]
PHST- 2009/02/14 09:00 [pubmed]
PHST- 2009/08/14 09:00 [medline]
PHST- 2009/02/13 00:00 [pmc-release]
AID - 669 [pii]
AID - 10.1007/s00262-009-0669-8 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2009 Oct;58(10):1599-608. doi: 
      10.1007/s00262-009-0669-8. Epub 2009 Feb 13.